ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin

ACADIA Pharmaceuticals Inc. has announced the initiation of its first Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson's disease psychosis, PDP.

Pimavanserin tartrate, previously referred to as ACP-103, is a novel, potent, and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a treatment for PDP.

The Phase III trial is a multi-center, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of pimavanserin in approximately 240 patients with PDP. Patients in the trial will be randomized to three different study arms, which will include two different doses of pimavanserin and one placebo arm. Patients will receive oral doses of either pimavanserin or placebo once daily for six weeks in addition to stable doses of their existing dopamine replacement therapy.

For further information please contact:

Bo-Ragner Tolf,

Vice President

Tel: +46 40 601 34 00

Email: btolf@acadia-pharm.com

Or visit: http://www.acadia-pharm.com